Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
Director departure
|
|
REVELATION BIOSCIENCES, INC.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 10/02/2023 |
8-K
| Quarterly results |
| 09/28/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/11/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023 San Diego, CA – August 11, 2023 – Revelation Biosciences Inc. , a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three and six months ended June 30, 2023 financial results. Results of Operations As of June 30, 2023, Revelation had $15.7 million in cash and cash equivalents, compared to $5.3 million as of December 31, 2022. The increase in cash and cash equivalents was primarily due to net cash received from financing activities, offset primarily by cash used for operating activities. Based on current operating plans and projections, Revelation believes that its current cash and cash ..." |
|
| 08/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 07/14/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/07/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 06/29/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders San Diego, CA – June 29, 2023 – Revelation Biosciences Inc. , a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reminded stockholders that the virtual Annual Meeting of Stockholders is scheduled for Friday, July 7, 2023, at 1:00 p.m. Eastern Time and urges all stockholders to vote now. YOUR VOTE IS IMPORTANT - NO MATTER HOW MANY SHARES YOU OWN, HOW FEW SHARES YOU OWN, OR IF YOU VOTE YOUR SHARES FOR, AGAINST OR ABSTAIN Important Information This communication may be deemed to be solicitation material in connection with the proposals to be considered at the Annual Meeting. In connection with..." |
|
| 06/12/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/25/2023 |
8-K
| Investor presentation |
| 05/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 05/05/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/25/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/03/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G
| AXA IM Prime Impact Master Fund I SCA SICAV-RAIF reports a 8.3% stake in Revelation Biosciences, Inc. |
| 02/14/2023 |
5
| AXA IM Prime Impact Master Fund I SCA SICAV-RAIF (Former 10% Owner) has filed a Form 5 on REVELATION BIOSCIENCES, INC. |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/09/2023 |
S-1MEF
| Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]: |
| 02/09/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 01/31/2023 |
8-K
| Quarterly results |
| 01/31/2023 |
SC 13G/A
| Linden Capital L.P. reports a 3% stake in Revelation Biosciences, Inc. |
| 01/13/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/13/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 01/10/2023 |
8-K
| Investor presentation |
| 01/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/30/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 12/21/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...|
Docs:
|
"REVELATION BIOSCIENCES, INC. CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Revelation Biosciences, Inc., a Delaware corporation , that the following resolution was duly adopted by the board of directors of the Corporation , in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware, as amended on December 14, 2022, which resolution provides for the creation of a series of the Corporation’s Preferred Stock, par value $0.001 per share, which is designated as “Series A Preferred Stock,” with the rights, preferences, privileges and restrictions set forth therein. WHEREAS, the Third Amended and Rest...",
"Revelation Biosciences, Inc. Series A Preferred Stock SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENT THIS AGREEMENT, dated as of December 19, 2022, is by and between Revelation Biosciences, Inc., a Delaware corporation , and the undersigned subscriber . In consideration of the mutual promises contained herein, and other good, valuable and adequate consideration, the parties hereto agree as follows: 1. Agreement of Sale; Closing. The Company agrees to sell to Subscriber, and Subscriber agrees to purchase from the Company, one share of the Company’s Series A Preferred Stock, par value $0.001 per share , which Securities shall have the rights, preferences, privileges and restrictions set forth in the Certificate of Designation attached hereto as Exhibit A . Subscriber hereby acknowledge..." |
|
| 12/20/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
|
|
|